{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:36:08Z","timestamp":1791239768369,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":113,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["297094"],"award-info":[{"award-number":["297094"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["333284"],"award-info":[{"award-number":["333284"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005633","name":"Syd\u00e4ntutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Reports"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.toxrep.2023.04.013","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T14:08:02Z","timestamp":1682431682000},"page":"521-528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Dasatinib targets c-Src kinase in cardiotoxicity"],"prefix":"10.1016","volume":"10","author":[{"given":"Manar","family":"Elmadani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Raatikainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orvokki","family":"Mattila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarja","family":"Alakoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarkko","family":"Piuhola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirjo","family":"\u00c5str\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Tenhunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Magga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risto","family":"Kerkel\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17\u201318","key":"10.1016\/j.toxrep.2023.04.013_bib1","first-page":"778","article-title":"Cardiotoxicity of the new cancer therapeutics - mechanisms of, and approaches to, the problem","volume":"13","author":"Force","year":"2008","journal-title":"Drug Disco"},{"issue":"2","key":"10.1016\/j.toxrep.2023.04.013_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrd3252","article-title":"Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes","volume":"10","author":"Force","year":"2011","journal-title":"NatRevDrug Disco"},{"issue":"1","key":"10.1016\/j.toxrep.2023.04.013_bib3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.toxrep.2023.04.013_bib4","first-page":"908","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkela","year":"2006","journal-title":"NatMed"},{"issue":"9604","key":"10.1016\/j.toxrep.2023.04.013_bib5","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.toxrep.2023.04.013_bib6","first-page":"1","article-title":"Cardiovascular side effects of cancer therapies: a position statement from the heart failure association of the European Society of Cardiology","volume":"13","author":"Eschenhagen","year":"2011","journal-title":"EurJHeart Fail"},{"issue":"23","key":"10.1016\/j.toxrep.2023.04.013_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018143","article-title":"Cardiotoxicity and cardiovascular biomarkers in patients with breast cancer: data from the GeparOcto-GBG 84 trial","volume":"9","author":"Ruger","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"22","key":"10.1016\/j.toxrep.2023.04.013_bib8","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.toxrep.2023.04.013_bib9","doi-asserted-by":"crossref","first-page":"l223","DOI":"10.1136\/bmj.l223","article-title":"Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study","volume":"364","author":"Taylor","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.toxrep.2023.04.013_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106037","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update","volume":"175","author":"Roskoski","year":"2022","journal-title":"Pharm. Res"},{"issue":"1","key":"10.1016\/j.toxrep.2023.04.013_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.toxrep.2023.04.013_bib12","first-page":"1046","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"NatBiotechnol"},{"issue":"3","key":"10.1016\/j.toxrep.2023.04.013_bib13","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1073\/pnas.77.3.1311","article-title":"Transforming gene product of Rous sarcoma virus phosphorylates tyrosine","volume":"77","author":"Hunter","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.toxrep.2023.04.013_bib14","article-title":"Src family kinases (SFKs): critical regulators of microglial homeostatic functions and neurodegeneration in Parkinson's and Alzheimer's diseases","author":"Portugal","year":"2021","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.toxrep.2023.04.013_bib15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12964-021-00750-x","article-title":"Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition","volume":"19","author":"Ortiz","year":"2021","journal-title":"Cell Commun. Signal"},{"issue":"12","key":"10.1016\/j.toxrep.2023.04.013_bib16","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1128\/MCB.25.12.5031-5039.2005","article-title":"Active Src elevates the expression of beta-catenin by enhancement of cap-dependent translation","volume":"25","author":"Karni","year":"2005","journal-title":"Mol. Cell Biol."},{"issue":"22","key":"10.1016\/j.toxrep.2023.04.013_bib17","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1158\/1078-0432.CCR-09-0767","article-title":"Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer","volume":"15","author":"Byers","year":"2009","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.toxrep.2023.04.013_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/35070042","article-title":"p190 RhoGAP is the principal Src substrate in brain and regulates axon outgrowth, guidance and fasciculation","volume":"3","author":"Brouns","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.toxrep.2023.04.013_bib19","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3389\/fphar.2020.00891","article-title":"A comprehensive review of clinical cardiotoxicity incidence of FDA-approved small-molecule kinase inhibitors","volume":"11","author":"Jin","year":"2020","journal-title":"Front Pharm."},{"issue":"12","key":"10.1016\/j.toxrep.2023.04.013_bib20","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.toxrep.2023.04.013_bib21","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/02841860903229124","article-title":"Cardiotoxicity induced by tyrosine kinase inhibitors","volume":"48","author":"Orphanos","year":"2009","journal-title":"Acta Oncol."},{"issue":"10","key":"10.1016\/j.toxrep.2023.04.013_bib22","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nsmb.1486","article-title":"Activation of tyrosine kinases by mutation of the gatekeeper threonine","volume":"15","author":"Azam","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"11","key":"10.1016\/j.toxrep.2023.04.013_bib23","first-page":"691","article-title":"Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases","volume":"4","author":"Apsel","year":"2008","journal-title":"NatChemBiol"},{"issue":"7","key":"10.1016\/j.toxrep.2023.04.013_bib24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/2159-8290.CD-15-1442","article-title":"Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma","volume":"6","author":"Saha","year":"2016","journal-title":"Cancer Disco"},{"issue":"21","key":"10.1016\/j.toxrep.2023.04.013_bib25","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013018","article-title":"Novel screening method identifies PI3Kalpha, mTOR, and IGF1R as key kinases regulating cardiomyocyte survival","volume":"8","author":"Elmadani","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.toxrep.2023.04.013_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccr.2009.05.017","article-title":"Latent bone metastasis in breast cancer tied to Src-dependent survival signals","volume":"16","author":"Zhang","year":"2009","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.toxrep.2023.04.013_bib27","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1172\/JCI86249","article-title":"Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension","volume":"126","author":"Guignabert","year":"2016","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.toxrep.2023.04.013_bib28","first-page":"127","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"NatBiotechnol"},{"issue":"1\u20133","key":"10.1016\/j.toxrep.2023.04.013_bib29","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ejphar.2011.05.078","article-title":"Multiple signalling pathways underlie the protective effect of levosimendan in cardiac myocytes","volume":"667","author":"Markou","year":"2011","journal-title":"Eur. J. Pharm."},{"issue":"3","key":"10.1016\/j.toxrep.2023.04.013_bib30","first-page":"237","article-title":"beta2-Adrenergic receptor-induced transactivation of epidermal growth factor receptor and platelet-derived growth factor receptor via Src kinase promotes rat cardiomyocyte survival","volume":"36","author":"Chen","year":"2012","journal-title":"Cell BiolInt"},{"issue":"3","key":"10.1016\/j.toxrep.2023.04.013_bib31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.tips.2011.11.002","article-title":"Targeting Src family kinases in anti-cancer therapies: turning promise into triumph","volume":"33","author":"Zhang","year":"2012","journal-title":"Trends Pharm. Sci."},{"issue":"5","key":"10.1016\/j.toxrep.2023.04.013_bib32","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1161\/HYPERTENSIONAHA.116.07699","article-title":"c-Src inhibition improves cardiovascular function but not remodeling or fibrosis in angiotensin II-induced hypertension","volume":"68","author":"Callera","year":"2016","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.toxrep.2023.04.013_bib33","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jacc.2013.10.081","article-title":"c-Src kinase inhibition reduces arrhythmia inducibility and connexin43 dysregulation after myocardial infarction","volume":"63","author":"Rutledge","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.toxrep.2023.04.013_bib34","doi-asserted-by":"crossref","first-page":"6449","DOI":"10.1210\/en.2008-0292","article-title":"Beta-adrenergic receptor mediated protection against doxorubicin-induced apoptosis in cardiomyocytes: the impact of high ambient glucose","volume":"149","author":"Yano","year":"2008","journal-title":"Endocrinology"},{"issue":"8","key":"10.1016\/j.toxrep.2023.04.013_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104888","article-title":"Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an in vitro study","volume":"9","author":"Kobashigawa","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.toxrep.2023.04.013_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/cells9092001","article-title":"PIM1 promotes survival of cardiomyocytes by upregulating c-kit protein expression","volume":"9","author":"Ebeid","year":"2020","journal-title":"Cells"},{"issue":"37","key":"10.1016\/j.toxrep.2023.04.013_bib37","doi-asserted-by":"crossref","first-page":"24037","DOI":"10.1074\/jbc.273.37.24037","article-title":"Mechanical stretch induces hypertrophic responses in cardiac myocytes of angiotensin II type 1a receptor knockout mice","volume":"273","author":"Kudoh","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.toxrep.2023.04.013_bib38","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/1078-0432.CCR-08-0905","article-title":"Mutations and response to epidermal growth factor receptor inhibitors","volume":"15","author":"Laurent-Puig","year":"2009","journal-title":"ClinCancer Res"},{"issue":"4","key":"10.1016\/j.toxrep.2023.04.013_bib39","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1152\/physrev.00054.2009","article-title":"Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale","volume":"90","author":"Rose","year":"2010","journal-title":"Physiol. Rev."},{"issue":"6","key":"10.1016\/j.toxrep.2023.04.013_bib40","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/01.RES.86.6.692","article-title":"Inhibition of extracellular signal-regulated kinase enhances Ischemia\/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart","volume":"86","author":"Yue","year":"2000","journal-title":"Circ. Res"},{"issue":"5","key":"10.1016\/j.toxrep.2023.04.013_bib41","doi-asserted-by":"crossref","first-page":"H1236","DOI":"10.1152\/ajpheart.00100.2009","article-title":"ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice","volume":"296","author":"Das","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"16","key":"10.1016\/j.toxrep.2023.04.013_bib42","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1161\/01.CIR.0000127126.73759.23","article-title":"MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo","volume":"109","author":"Lips","year":"2004","journal-title":"Circulation"},{"issue":"35","key":"10.1016\/j.toxrep.2023.04.013_bib43","doi-asserted-by":"crossref","first-page":"14074","DOI":"10.1073\/pnas.0610906104","article-title":"Genetic inhibition of cardiac ERK1\/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo","volume":"104","author":"Purcell","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.toxrep.2023.04.013_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092164","article-title":"ERK: a key player in the pathophysiology of cardiac hypertrophy","volume":"20","author":"Gallo","year":"2019","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.toxrep.2023.04.013_bib45","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/01.RES.0000012702.90501.8D","article-title":"Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCepsilon-MAPK interactions and differential MAPK activation in PKCepsilon-induced cardioprotection","volume":"90","author":"Baines","year":"2002","journal-title":"Circ. Res"},{"issue":"18","key":"10.1016\/j.toxrep.2023.04.013_bib46","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.1073\/pnas.0401833101","article-title":"Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity","volume":"101","author":"Aries","year":"2004","journal-title":"ProcNatlAcadSciUSA"},{"issue":"10","key":"10.1016\/j.toxrep.2023.04.013_bib47","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrclinonc.2009.129","article-title":"Src kinases as therapeutic targets for cancer","volume":"6","author":"Kim","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.toxrep.2023.04.013_bib48","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccell.2019.01.007","article-title":"Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance","volume":"35","author":"Cooper","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.toxrep.2023.04.013_bib49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10428194.2018.1466294","article-title":"Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells","volume":"60","author":"Gover-Proaktor","year":"2019","journal-title":"Leuk. Lymphoma"}],"container-title":["Toxicology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750023000495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750023000495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T15:49:00Z","timestamp":1762012140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214750023000495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":49,"alternative-id":["S2214750023000495"],"URL":"https:\/\/doi.org\/10.1016\/j.toxrep.2023.04.013","relation":{},"ISSN":["2214-7500"],"issn-type":[{"value":"2214-7500","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dasatinib targets c-Src kinase in cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"Toxicology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxrep.2023.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}